Paul Boni is the Chief Operating Officer at OrphAI Therapeutics. Mr. Boni most recently served as CFO of Manus Bio, a privately held synthetic biology company where he oversaw the acquisition of NutraSweet, as well as significant expansion of the company’s operations into development and manufacturing. He began his career as a buy- and sell-side analyst covering biotechnology and healthcare companies, where he developed a deep understanding of fundraising, capital markets, and the finance ecosystem that supports growing biotechnology companies. Mr. Boni previously oversaw investor development and strategy at ContraFect Corporation, a publicly traded company focused on anti-infective drug development, and led a global team of nearly 400 associates at Grail Research, a strategic research/consulting group. Mr. Boni has a B.S. in Biology from Harvard.
